Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial
Article Information
vol. 41 no. 3 538-546
PubMed
Published By
Print ISSN
Online ISSN
History
- Received August 1, 2017
- Accepted November 27, 2017
- Published in print February 20, 2018.
- Published online ahead of print January 3, 2018.
Article Versions
- Previous version (January 3, 2018 - 06:45).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2018 by the American Diabetes Association. http://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.
Author Information
- Eiichi Araki1⇑,
- Shizuya Yamashita2,3,
- Hidenori Arai4,
- Koutaro Yokote5,
- Jo Satoh6,
- Toyoshi Inoguchi7,
- Jiro Nakamura8,
- Hiroshi Maegawa9,
- Narihito Yoshioka10,
- Yukio Tanizawa11,
- Hirotaka Watada12,
- Hideki Suganami13 and
- Shun Ishibashi14
- 1Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
- 2Department of Community Medicine and Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
- 3Rinku General Medical Center, Osaka, Japan
- 4National Center for Geriatrics and Gerontology, Aichi, Japan
- 5Department of Clinical Cell Biology and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan
- 6Tohoku Medical and Pharmaceutical University Wakabayashi Hospital, Miyagi, Japan
- 7Fukuoka Health Promotion Support Center, Fukuoka, Japan
- 8Division of Diabetes, Department of Internal Medicine, Aichi Medical University, Aichi, Japan
- 9Department of Medicine, Shiga University of Medical Science, Shiga, Japan
- 10Division of Diabetes and Endocrinology, Department of Medicine, Sapporo Medical Center, NTT East Corporation, Hokkaido, Japan
- 11Division of Endocrinology, Metabolism, Hematological Science and Therapeutics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan
- 12Department of Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan
- 13Clinical Data Science Department, Kowa Company, Ltd., Tokyo, Japan
- 14Division of Endocrinology and Metabolism, Department of Medicine, Jichi Medical University, Tochigi, Japan
- Corresponding author: Eiichi Araki, earaki{at}gpo.kumamoto-u.ac.jp.
Statistics from Altmetric.com
Article usage
In this Issue
March 2018, 41(3)
Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial
